Literature DB >> 10202824

Persistent alterations in T-cell repertoire, cytokine and chemokine receptor gene expression after 1 year of highly active antiretroviral therapy.

F Martinon1, C Michelet, I Peguillet, Y Taoufik, P Lefebvre, C Goujard, J G Guillet, J F Delfraissy, O Lantz.   

Abstract

OBJECTIVES: To examine T-cell repertoire modifications, the evolution of T-helper (TH)1/TH2 cytokine imbalance and modifications in chemokine receptor expression when the viral load is decreased by 2-3 log10 copies/ml under highly active antiretroviral therapy (HAART).
DESIGN: Sixteen patients previously treated with zidovudine and lamivudine, with CD4 cells below 300 x 10(6)/l and viraemia above 30000 copies/ml were treated by saquinavir and ritonavir together with both reverse transcriptase (RT) inhibitors (ANRS 069 trial). T-cell repertoire, chemokine receptor and lymphokine expression were studied from peripheral blood mononuclear cells sampled at weeks 0, 24 and 48.
METHODS: T-cell repertoire study was carried out using the Immunoscope method. Interleukin (IL)-12 receptor beta2, CC-chemokine receptor (CCR)-3, CXC-chemokine receptor-4 and CCR-5 expression in CD4+ cells was measured by kinetic quantitative PCR and IL-2, IL-4, IL-10, IL-13, interferon (IFN)-gamma were measured using a quantitative RT-PCR assay with homologous internal standards.
RESULTS: Repertoire alterations were more frequent in CD4- than in CD4+ cells and persisted despite undetectable viraemia. Increased CCR-3 expression and spontaneous IFN-gamma as well as mitogenic induced IL-13 were observed at baseline and decreased slightly under HAART.
CONCLUSION: The CD8+ cell repertoire alterations were profound, whereas the CD4+ cell alterations were moderate and both persisted unchanged under HAART. The TH1/TH2 imbalance was more related to TH2 over-expression than to TH1 deficiency and persisted for at least 1 year under HAART.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10202824     DOI: 10.1097/00002030-199902040-00006

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  10 in total

Review 1.  Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy.

Authors:  G R Kaufmann; J Zaunders; D A Cooper
Journal:  Sex Transm Infect       Date:  1999-08       Impact factor: 3.519

2.  T cell responses to highly active antiretroviral therapy defined by chemokine receptors expression, cytokine production, T cell receptor repertoire and anti-HIV T-lymphocyte activity.

Authors:  A Giovannetti; M Pierdominici; F Mazzetta; S Salemi; M Marziali; D Kuonen; F Iebba; E A Lusi; A Cossarizza; F Aiuti
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

3.  Decreases in plasma TNF-alpha level and IFN-gamma mRNA level in peripheral blood mononuclear cells (PBMC) and an increase in IL-2 mRNA level in PBMC are associated with effective highly active antiretroviral therapy in HIV-infected patients.

Authors:  P Brazille; N Dereuddre-Bosquet; C Leport; P Clayette; O Boyer; J-L Vildé; D Dormont; O Benveniste
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

4.  Cytokine analysis at the single cell level and lymphoproliferative responses to mycobacterial antigens in HIV-1 patients with successful virologic response to potent antiretrovirals.

Authors:  C Amiel; J P Kusnierz; Y Mouton; G Rook; J Stanford; M Singh; A Capron; G M Bahr
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

5.  Preservation of clonal heterogeneity of the Pneumocystis carinii-specific CD4 T cell repertoire in HIV infected, asymptomatic individuals.

Authors:  G Li Pira; D Fenoglio; L Bottone; P Terranova; E Pontali; F Caroli; M Seri; J-C Cailliez; G Koopman; R Accolla; F del Galdo; G Abbate; R de Palma; F Manca
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

6.  An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy.

Authors:  N M Keane; P Price; S Lee; S F Stone; M A French
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

7.  Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.

Authors:  Daria Trabattoni; Sergio Lo Caputo; Mara Biasin; Elena Seminari; Massimo Di Pietro; Giovanni Ravasi; Francesco Mazzotta; Renato Maserati; Mario Clerici
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

8.  Persistent HIV-1 replication does not explain low levels of T-cell interferon-gamma mRNA and elevated serum NO(2) (-)/NO(3) (-) in patients with stable CD4 T-cell responses to HAART.

Authors:  S Lee; C-A Almeida; M A H French; P Price
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

9.  Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5.

Authors:  Dawn A Maier; Andrea L Brennan; Shuguang Jiang; Gwendolyn K Binder-Scholl; Gary Lee; Gabriela Plesa; Zhaohui Zheng; Julio Cotte; Carmine Carpenito; Travis Wood; S Kaye Spratt; Dale Ando; Philip Gregory; Michael C Holmes; Elena E Perez; James L Riley; Richard G Carroll; Carl H June; Bruce L Levine
Journal:  Hum Gene Ther       Date:  2013-03-06       Impact factor: 5.695

10.  An invariant T cell receptor alpha chain defines a novel TAP-independent major histocompatibility complex class Ib-restricted alpha/beta T cell subpopulation in mammals.

Authors:  F Tilloy; E Treiner; S H Park; C Garcia; F Lemonnier; H de la Salle; A Bendelac; M Bonneville; O Lantz
Journal:  J Exp Med       Date:  1999-06-21       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.